Combining clinical medicine, continuous glucose monitoring, and evidence-based nutrition to treat obesity, diabetes, and cardiometabolic risk — where numbers tell the full story.
Every metabolic patient is a phenotype, not just a diagnosis. The work is in reading the data closely enough to find which lever to pull.
Founder and Director of IMPA — a professional body advancing the practice and education of metabolic medicine globally, with the IMPA Conclave as its flagship annual event.
Founder & Director · IMPAPrecision obesity medicine combining GLP-1/GIP receptor agonist therapy (semaglutide, tirzepatide), body composition assessment, and sarcopenia-aware treatment using AWGS 2019 criteria.
GLP-1 · Tirzepatide · MNTComprehensive T2DM management including SGLT2i, GLP-1 agonists, and insulin optimization. Special focus on MASLD, cardiometabolic risk, and South Asian metabolic profiles.
T2DM · MASLD · CardiometabolicEvidence-based dietary prescription integrated with pharmacotherapy. Protein-first strategy, carbohydrate phenotyping, and drug-nutrient interaction management for GLP-1 and SGLT2i regimens.
MNT · Protein-first · Carb phenotypingCourse Director of a structured CME program for dieticians, co-facilitated with Dt. Sapna Kamdar. Faculty also at PHFI and MUHS Diabetology & Obesity Fellowship Programs, and DNB Teacher.
Course Director · PHFI · MUHS · DNBApplying AI and digital health tools to metabolic care — from CGM phenotype auto-classification to predictive GLP-1 response modelling. Currently enrolled in the Johns Hopkins AI in Healthcare Programme.
Johns Hopkins · AI · Digital HealthArticles, presentations, and downloadable resources — for clinicians who want depth and patients who want clarity.
How the iCAN framework identifies Dawn Riser, Meal Reactor, Night Diver and 4 other patterns — and what each means for therapy.
A plain-language guide to reading your glucose trace — what the spikes mean, what the flatlines mean, and what to do about both.
The questions every patient on semaglutide or tirzepatide asks in the first 3 months — and the clinical answers they deserve.
Consultations available at two locations in Mumbai. Referrals and speaking enquiries welcome via the contact form.
For conference invitations, CME programme collaborations, pharma advisory roles, or media requests — use the form below or email directly.
Email Dr. Pahuja →